FIDELIO-DKD included approximately 5700 persons with T2DM and CKD who were receiving maximum tolerated doses of an ACE inhibitor or ARB and had a serum potassium concentration ≤ of 4.8 mmol/L (Figure 3) [29]. Here, ACE is linked to chronic kidney disease.